The prevalence of osteoporosis in men with prostate cancer on androgen deprivation therapy: a systematic review and meta-analysis

Lassemillante, Annie-Claude, Hooper, John, Prins, John, Doi, Suhail and Wright, Olivia (2013). The prevalence of osteoporosis in men with prostate cancer on androgen deprivation therapy: a systematic review and meta-analysis. In: Prostate Cancer World Congress & 14th Australasian Prostate Cancer Conference, Melbourne Australia, (35-35). 6–10 August 2013. doi:10.1111/bju.12293


Author Lassemillante, Annie-Claude
Hooper, John
Prins, John
Doi, Suhail
Wright, Olivia
Title of paper The prevalence of osteoporosis in men with prostate cancer on androgen deprivation therapy: a systematic review and meta-analysis
Conference name Prostate Cancer World Congress & 14th Australasian Prostate Cancer Conference
Conference location Melbourne Australia
Conference dates 6–10 August 2013
Journal name BJU International   Check publisher's open access policy
Place of Publication West Sussex United Kingdom
Publisher Wiley-Blackwell Publishing
Publication Year 2013
Sub-type Published abstract
DOI 10.1111/bju.12293
Open Access Status
ISSN 1464-4096
1464-410X
Volume 112
Start page 35
End page 35
Total pages 1
Language eng
Formatted Abstract/Summary
Background
Androgen deprivation therapy (ADT), commonly used in the treatment of prostate cancer, is associated with increased morbidity such as metabolic syndrome, erectile dysfunction and bone loss. The decrease in bone mineral density has been quantified as 1.5–4% within 12 months of treatment initiation and 2% every year thereafter. Consequently, osteopenia and osteoporosis are highly prevalent in this patient group.
Objectives
The aim of this meta-analysis is to determine the prevalence of osteoporosis in men with prostate cancer on ADT. The secondary aim is to explain why the prevalence of osteoporosis varies in this patient group.
Methods
The Pubmed, EmBase and Scopus databases were searched for published literature on PCa and bone health, with a focus on osteoporosis. The studies were quality assessed and meta-analysed using the quality effects model.
Results
Twelve studies were reviewed and it was found that the prevalence of osteoporosis in men with prostate cancer on ADT varied between 9% and 53%. A higher prevalence of osteoporosis was identified in studies reporting on longer duration of ADT and anti-androgen mono-therapy. Ethnicity, DXA machine and skeletal region used to measure bone mass also explained the disparity in osteoporosis prevalence.
Conclusions
Variation in the prevalence of osteoporosis in men with prostate cancer on ADT, highlights the importance of bone monitoring early in this disease rather than when treatment is initiated.
Q-Index Code EX
Q-Index Status Provisional Code
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Google Scholar Search Google Scholar
Created: Sun, 11 Aug 2013, 00:14:34 EST by System User on behalf of School of Human Movement and Nutrition Sciences